Skip to Main Content
Table 2—

All-cause mortality and renal, cardiovascular, and composite end points in 4,421 Chinese type 2 diabetic patients without macrovascular disease and end-stage renal disease

Total cohorteGFR (ml/min per 1.73 m2)
P for trend
≥9060–8930–5915–29
n 4,421 2,257 1,636 457 71  
All-cause mortality (%) 2.5 (2.0–2.9) 1.2 (0.8–1.7) 2.6 (1.9–3.4) 5.5 (3.3–7.6) 18.3 (9.1–27.5) <0.001 
Cardiovascular end points (%) 4.8 (4.2–5.5) 2.6 (2.0–3.3) 5.4 (4.3–6.5) 10.3 (7.5–13.1) 25.4 (15.0–35.7) <0.001 
Renal end points (%) 4.8 (4.1–5.4) 1.7 (1.1–2.2) 3.0 (2.1–3.8) 16.5 (12.9–20.1) 68.2 (56.6–79.7) <0.001 
Composite end points (%) 9.6 (8.7–10.5) 5.0 (4.1–6.0) 9.0 (7.6–10.5) 23.9 (19.8–28.0) 75.8 (65.1–86.4) <0.001 
Total cohorteGFR (ml/min per 1.73 m2)
P for trend
≥9060–8930–5915–29
n 4,421 2,257 1,636 457 71  
All-cause mortality (%) 2.5 (2.0–2.9) 1.2 (0.8–1.7) 2.6 (1.9–3.4) 5.5 (3.3–7.6) 18.3 (9.1–27.5) <0.001 
Cardiovascular end points (%) 4.8 (4.2–5.5) 2.6 (2.0–3.3) 5.4 (4.3–6.5) 10.3 (7.5–13.1) 25.4 (15.0–35.7) <0.001 
Renal end points (%) 4.8 (4.1–5.4) 1.7 (1.1–2.2) 3.0 (2.1–3.8) 16.5 (12.9–20.1) 68.2 (56.6–79.7) <0.001 
Composite end points (%) 9.6 (8.7–10.5) 5.0 (4.1–6.0) 9.0 (7.6–10.5) 23.9 (19.8–28.0) 75.8 (65.1–86.4) <0.001 

Data are percent (95% CI). Cardiovascular end points were defined as hospitalizations due to ischemic heart disease, congestive heart failure, stroke, and revascularization procedures. Renal end points were defined as reduction in eGFR by >50% or progression to eGFR <15 ml/min per 1.73 m2 (stage 5) or renal dialysis or death secondary to renal causes. Composite end points were that of all-cause mortality and cardiovascular and renal end points.

Close Modal

or Create an Account

Close Modal
Close Modal